Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer

Giuliano Mariani, Sonia Di Sacco, Duccio Volterrani, Lorella Di Luca, Simona Buralli, Rossella Di Stefano, Janina Baranowska-Kortylewicz, Danilo Bonora, Federica Matteucci, Sergio Ricci, C. Riccardo Bellina, Alfredo Falcone, Piero A. Salvadori, Franco Mosca, S. J. Adelstein, Amin I. Kassis

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We previously showed the tumor-targeting potential of the 125I-labeled thymidine analog 5-iodo-2′-deoxyuridine (IUdR) injected intratumorally in patients with high tumor-cell kinetics. In this study, we evaluated the tumor incorporation of [123I]IUdR infused intra-arterially in patients with liver metastases from colorectal cancer. Methods: Iodine-123-IUdR (110-300 MBq, 3-8 mCi, specific activity, 150-200 Ci/μmole) was infused into the hepatic artery of 16 patients with inoperable liver metastases over 30-45 min through a permanent intra-arterial catheter. A dynamic sequence during infusion, spot images, whole-body scans and SPECT acquisitions were recorded up to 42 hr. Blood and urine samples were obtained for biodistribution and HPLC analyses. Results: In the 14 patients with adequate tumor perfusion patterns, tumor uptake reached 2%-17.6% ID at the end of infusion. After a washout phase that lasted 18-20 hr, incorporated radioactivity remained steadily associated with the tumor lesions until at least 42 hr after infusion (about 1.4%-11.1% ID). HPLC analysis indicated a virtually 100% first-pass hepatic deiodination of unincorporated [123I]IUdR (about 80%-95% ID recovered in the 42-hr urine). No significant uptake was detected in the bone marrow or in other normal dividing tissues. Conclusion: These results encourage further studies to enable dosimetric estimates, optimization of dose regimens, and examination of the therapeutic potential of Auger-electron-emitter-labeled IUdR in cancer therapy utilizing this type of approach.

Original languageEnglish (US)
Pages (from-to)22S-25S
JournalJournal of Nuclear Medicine
Volume37
Issue number4 SUPPL.
StatePublished - Apr 1 1996

Fingerprint

Intra Arterial Infusions
Deoxyuridine
Idoxuridine
Colorectal Neoplasms
Neoplasm Metastasis
Liver
Neoplasms
High Pressure Liquid Chromatography
Urine
Whole Body Imaging
Hepatic Artery
Single-Photon Emission-Computed Tomography
Iodine
Thymidine
Radioactivity
Catheters
Perfusion
Bone Marrow
Electrons
Therapeutics

Keywords

  • Colorectal cancer
  • Intra-arterial infusion
  • Iodine-123-IUdR
  • Liver metastases
  • Locoregional administration

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Mariani, G., Di Sacco, S., Volterrani, D., Di Luca, L., Buralli, S., Di Stefano, R., ... Kassis, A. I. (1996). Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. Journal of Nuclear Medicine, 37(4 SUPPL.), 22S-25S.

Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. / Mariani, Giuliano; Di Sacco, Sonia; Volterrani, Duccio; Di Luca, Lorella; Buralli, Simona; Di Stefano, Rossella; Baranowska-Kortylewicz, Janina; Bonora, Danilo; Matteucci, Federica; Ricci, Sergio; Riccardo Bellina, C.; Falcone, Alfredo; Salvadori, Piero A.; Mosca, Franco; Adelstein, S. J.; Kassis, Amin I.

In: Journal of Nuclear Medicine, Vol. 37, No. 4 SUPPL., 01.04.1996, p. 22S-25S.

Research output: Contribution to journalArticle

Mariani, G, Di Sacco, S, Volterrani, D, Di Luca, L, Buralli, S, Di Stefano, R, Baranowska-Kortylewicz, J, Bonora, D, Matteucci, F, Ricci, S, Riccardo Bellina, C, Falcone, A, Salvadori, PA, Mosca, F, Adelstein, SJ & Kassis, AI 1996, 'Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer', Journal of Nuclear Medicine, vol. 37, no. 4 SUPPL., pp. 22S-25S.
Mariani G, Di Sacco S, Volterrani D, Di Luca L, Buralli S, Di Stefano R et al. Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. Journal of Nuclear Medicine. 1996 Apr 1;37(4 SUPPL.):22S-25S.
Mariani, Giuliano ; Di Sacco, Sonia ; Volterrani, Duccio ; Di Luca, Lorella ; Buralli, Simona ; Di Stefano, Rossella ; Baranowska-Kortylewicz, Janina ; Bonora, Danilo ; Matteucci, Federica ; Ricci, Sergio ; Riccardo Bellina, C. ; Falcone, Alfredo ; Salvadori, Piero A. ; Mosca, Franco ; Adelstein, S. J. ; Kassis, Amin I. / Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer. In: Journal of Nuclear Medicine. 1996 ; Vol. 37, No. 4 SUPPL. pp. 22S-25S.
@article{e22fb0a7fb6c4e5dbffe9f6c599823e3,
title = "Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer",
abstract = "We previously showed the tumor-targeting potential of the 125I-labeled thymidine analog 5-iodo-2′-deoxyuridine (IUdR) injected intratumorally in patients with high tumor-cell kinetics. In this study, we evaluated the tumor incorporation of [123I]IUdR infused intra-arterially in patients with liver metastases from colorectal cancer. Methods: Iodine-123-IUdR (110-300 MBq, 3-8 mCi, specific activity, 150-200 Ci/μmole) was infused into the hepatic artery of 16 patients with inoperable liver metastases over 30-45 min through a permanent intra-arterial catheter. A dynamic sequence during infusion, spot images, whole-body scans and SPECT acquisitions were recorded up to 42 hr. Blood and urine samples were obtained for biodistribution and HPLC analyses. Results: In the 14 patients with adequate tumor perfusion patterns, tumor uptake reached 2{\%}-17.6{\%} ID at the end of infusion. After a washout phase that lasted 18-20 hr, incorporated radioactivity remained steadily associated with the tumor lesions until at least 42 hr after infusion (about 1.4{\%}-11.1{\%} ID). HPLC analysis indicated a virtually 100{\%} first-pass hepatic deiodination of unincorporated [123I]IUdR (about 80{\%}-95{\%} ID recovered in the 42-hr urine). No significant uptake was detected in the bone marrow or in other normal dividing tissues. Conclusion: These results encourage further studies to enable dosimetric estimates, optimization of dose regimens, and examination of the therapeutic potential of Auger-electron-emitter-labeled IUdR in cancer therapy utilizing this type of approach.",
keywords = "Colorectal cancer, Intra-arterial infusion, Iodine-123-IUdR, Liver metastases, Locoregional administration",
author = "Giuliano Mariani and {Di Sacco}, Sonia and Duccio Volterrani and {Di Luca}, Lorella and Simona Buralli and {Di Stefano}, Rossella and Janina Baranowska-Kortylewicz and Danilo Bonora and Federica Matteucci and Sergio Ricci and {Riccardo Bellina}, C. and Alfredo Falcone and Salvadori, {Piero A.} and Franco Mosca and Adelstein, {S. J.} and Kassis, {Amin I.}",
year = "1996",
month = "4",
day = "1",
language = "English (US)",
volume = "37",
pages = "22S--25S",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Tumor targeting by intra-arterial infusion of 5-[123I]iodo-2′-deoxyuridine in patients with liver metastases from colorectal cancer

AU - Mariani, Giuliano

AU - Di Sacco, Sonia

AU - Volterrani, Duccio

AU - Di Luca, Lorella

AU - Buralli, Simona

AU - Di Stefano, Rossella

AU - Baranowska-Kortylewicz, Janina

AU - Bonora, Danilo

AU - Matteucci, Federica

AU - Ricci, Sergio

AU - Riccardo Bellina, C.

AU - Falcone, Alfredo

AU - Salvadori, Piero A.

AU - Mosca, Franco

AU - Adelstein, S. J.

AU - Kassis, Amin I.

PY - 1996/4/1

Y1 - 1996/4/1

N2 - We previously showed the tumor-targeting potential of the 125I-labeled thymidine analog 5-iodo-2′-deoxyuridine (IUdR) injected intratumorally in patients with high tumor-cell kinetics. In this study, we evaluated the tumor incorporation of [123I]IUdR infused intra-arterially in patients with liver metastases from colorectal cancer. Methods: Iodine-123-IUdR (110-300 MBq, 3-8 mCi, specific activity, 150-200 Ci/μmole) was infused into the hepatic artery of 16 patients with inoperable liver metastases over 30-45 min through a permanent intra-arterial catheter. A dynamic sequence during infusion, spot images, whole-body scans and SPECT acquisitions were recorded up to 42 hr. Blood and urine samples were obtained for biodistribution and HPLC analyses. Results: In the 14 patients with adequate tumor perfusion patterns, tumor uptake reached 2%-17.6% ID at the end of infusion. After a washout phase that lasted 18-20 hr, incorporated radioactivity remained steadily associated with the tumor lesions until at least 42 hr after infusion (about 1.4%-11.1% ID). HPLC analysis indicated a virtually 100% first-pass hepatic deiodination of unincorporated [123I]IUdR (about 80%-95% ID recovered in the 42-hr urine). No significant uptake was detected in the bone marrow or in other normal dividing tissues. Conclusion: These results encourage further studies to enable dosimetric estimates, optimization of dose regimens, and examination of the therapeutic potential of Auger-electron-emitter-labeled IUdR in cancer therapy utilizing this type of approach.

AB - We previously showed the tumor-targeting potential of the 125I-labeled thymidine analog 5-iodo-2′-deoxyuridine (IUdR) injected intratumorally in patients with high tumor-cell kinetics. In this study, we evaluated the tumor incorporation of [123I]IUdR infused intra-arterially in patients with liver metastases from colorectal cancer. Methods: Iodine-123-IUdR (110-300 MBq, 3-8 mCi, specific activity, 150-200 Ci/μmole) was infused into the hepatic artery of 16 patients with inoperable liver metastases over 30-45 min through a permanent intra-arterial catheter. A dynamic sequence during infusion, spot images, whole-body scans and SPECT acquisitions were recorded up to 42 hr. Blood and urine samples were obtained for biodistribution and HPLC analyses. Results: In the 14 patients with adequate tumor perfusion patterns, tumor uptake reached 2%-17.6% ID at the end of infusion. After a washout phase that lasted 18-20 hr, incorporated radioactivity remained steadily associated with the tumor lesions until at least 42 hr after infusion (about 1.4%-11.1% ID). HPLC analysis indicated a virtually 100% first-pass hepatic deiodination of unincorporated [123I]IUdR (about 80%-95% ID recovered in the 42-hr urine). No significant uptake was detected in the bone marrow or in other normal dividing tissues. Conclusion: These results encourage further studies to enable dosimetric estimates, optimization of dose regimens, and examination of the therapeutic potential of Auger-electron-emitter-labeled IUdR in cancer therapy utilizing this type of approach.

KW - Colorectal cancer

KW - Intra-arterial infusion

KW - Iodine-123-IUdR

KW - Liver metastases

KW - Locoregional administration

UR - http://www.scopus.com/inward/record.url?scp=0030115978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030115978&partnerID=8YFLogxK

M3 - Article

C2 - 8676199

AN - SCOPUS:0030115978

VL - 37

SP - 22S-25S

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 4 SUPPL.

ER -